TMC Bets Dosing Convenience, Field Force Synergies Will Help Oritavancin Prosper
This article was originally published in The Pink Sheet Daily
Executive Summary
The Medicines Co. held an analyst meeting Oct. 9 in large measure to broadcast the progress it has made diversifying away from its current chief revenue generator, the cardiovascular drug Angiomax. It’s betting that its first foray into antibiotics, the IV-administered drug oritavancin, will best competition because of dosing advantages, efficacy, and the sponsor’s deep expertise in the tumultuous hospital market
You may also be interested in...
Mirror, Mirror: Long-acting Antibiotics Dalbavancin, Oritavancin Emerging With Similar Profiles
Full results for Durata’s dalbavancin and The Medicine’s Co.’s oritavancin – both lipoglycopeptides – suggest the mode of administration is likely to become a key differentiating factor if the drugs are approved.
Mesoblast’s Late-Stage Pipeline Could Be Game Changing: Are Investors Paying Attention?
Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.
Ketamine May Shake Up The Treatment Of Major Depression
Pharmas have shied away from the challenging antidepressant market in recent years, but two late-stage ketamine-like candidates are leading the pack of novel agents in development.